INTRODUCTION
Paraneoplastic syndromes, associated with the distant effect of humoral factors produced by the tumour, are known to develop concomitantly with malignant tumors. The autoimmune syndromes are relatively rare paraneoplastic events. 1, 2 They are more common and better studied in lymphomas. 3, 4 There are only single reports of these in solid tumors.
The aim of the present study was to fi nd the frequency of autoimmune phenomena in solid tumors of various origin, location and status of the tumor.
PATIENTS AND METHODS
The present prospective study recruited 1083 patients diagnosed and treated in St George University Hospital in Plovdiv between 2010 and 2014.
The patient distribution by type of solid tumour was as follows: breast carcinoma -240, colon carcinoma -240, ovarian carcinoma -71, prostate carcinoma -55, lung carcinoma -95 and others. Patients with lymphomas were excluded from the study.
The diagnosis of autoimmune paraneoplastic phenomena is based on the following laboratory tests: for autoimmune hemolytic anemia -Coombs test (direct and indirect) and serological evidence of antierythrocyte antibodies; for immune thrombocytopenia -the platelet survival test and sequestration of platelets using chromium-51; for other autoimmune syndromes we studied the antinuclear antibodies, the rheumatoid factor, the serum complement C3, the lupus anticoagulant, the antineutrophil cytoplasmic antibodies, capillaroscopy and some other indicators of autoimmune aggression.
In the statistical analysis we determined the indicators of relative proportion. The structure of the patients' groups and the types of autoimmune complications are presented graphically.
RESULTS
We found an incidence of 1.29% for the autoimmune paraneoplastic syndromes in malignant solid tumors. The distribution by type of autoimmune disease shows high frequency of vasculitis (3/14 cases), autoimmune hemolytic anemias (3/14) and polyneuritis (3/14) . Immune thrombocytopenia, seronegative arthritis, psoriasis, polymyositis are less frequently recognised.
We found higher incidence of autoimmune phenomena in prostate carcinoma (9.09%) and ovarian carcinoma (5.6%) than in other solid tumors (Fig. 1) . Autoimmune paraneoplastic phenomena may occur metachronously (with some time elapsing between diagnosis of malignancy and onset of autoimmune complications, may range between 6 months to 6 years), and less rarely synchronously with the malignancy ( Table 1) . In a female patient we found autoimmune thrombocytopenia 22 years after successful treatment of ovarian cancer. This interval of time, and lack of data on recurrence of carcinoma give us grounds to assume that it is more likely to have a combination of a primary autoimmune disease with neoplasm, rather than paraneoplastic syndrome.
In most cases the paraneoplastic phenomena cooccur with a progressive disease or a metastatic disease (9/14) and respond favourably to therapy. 
DISCUSSION
The fi rst report of an autoimmune disorder appearing as a debut manifestation of a malignant tumour was made in 1916. 5 A lot of evidence has since been accumulated for a reciprocal interactive relationship between tumour and autoimmune disorders.
On the one hand, some autoimmune disorders have been found to have an increased risk of occurrence of neoplasms, usually after a prolonged period of time. 6, 7 Non-Hodgkin's lymphomas is very often found in patients with Sjögren's syndrome. Neoplastic hematological diseases and malignant tumors of the gastrointestinal tract develop in celiac disease, Crohn's disease and in chronic ulcerative hemorrhagic colitis. 8 It has been found that 8% of vasculitis patients develop cancer. 5 On the other hand, malignant tumors, and sometimes antineoplastic therapy, trigger immune dysregulation and create conditions for autoimmune complications. The immunosuppressive therapy has been considered to play a role as etiologic noxa for cancer. 9 It is believed that a key moment in the pathogenesis of autoimmune and malignant disorders is the inhibition of apoptosis. 10 In tumors this leads to induction of anti DNA antibodies and inhibition of T cell-protective function. Along with this pseudo-autoimmune status the tumors induce immunosuppression by IL-10, TGF-β, VEGF, modulate the function of macrophages and dendritic cells, which boosts the generation of metastases. 10 Some genetic disorders have been associated with the disrupted process of apoptosis. The malignant phenotype is associated with overexpression of Bcl-2 oncogene with anti-apoptosis effect, as well as a mutation of p-53 tumor suppressor gene that supports genome stability. Mutant Fas gene (inducer of apoptosis) is the reason for the occurrence of lymphomas. 11 In apoptosis-inducing PTEN genes there are mutated variants that predispose to the development of cancer. 12 The connecting link in the genetics of autoimmune diseases and tumors are the genes for glutathione S transferase. They encode enzymes that facilitate the metabolism of potentially toxic components. The mutations in these genes play a key role not only in carcinomas, but also in lupus erythematosus, rheumatoid arthritis and the myelodysplastic syndrome. Studying them makes it possible to identify genotypes with a higher risk for prostate cancer and carcinoma of the breast. 12 Criteria have been sought to differentiate the idiopathic autoimmune diseases from autoimmune paraneoplastic phenomena, emphasizing some atypical features (age, laboratory data). 5 The most salient difference is the chronology of their appearance. The autoimmune paraneoplastic phenomena (unlike primary autoimmune diseases) are characterized by either a synchronous or metachronous development (after) with the primary tumor.
The auto-aggression is directed against the socalled tumor associated antigens -oncoproteins (c-myc), antigens encoded by mutated 53 tumor suppressor gene, differentiating antigens, cell surface receptor (HER), onconeural antigens, cancer/testis antigens. Anti-DNA antibodies are the commonest diagnostic fi ndings -24% of neoplasms and 50% of breast carcinomas. 8, 9 Autoimmune paraneoplastic phenomena have been demonstrated in various tumours without any specifi city. They occur relatively more frequently in ovarian and prostate carcinomas. Autoimmune hemolytic anemia is more common in renal cell carcinoma and Kaposi sarcoma. 13 There is no consensus in the literature regarding the potential diagnostic and prognostic value of autoimmune phenomena. 12, 14 Some researchers have found them to precede immediately the diagnosis of tumors which is not supported by our study.
CONCLUSION
Paraneoplastic autoimmune phenomena were found in 1.29% of the cases of malignant solid tumors. They occur more frequently in carcinomas of the prostate and ovaries. Clinically, they manifest themselves in progression of the malignant tumor. They respond favourably to drug therapy or surgical treatment of the malignomas.
